Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.09
+0.12 (1.28%)
Nov 21, 2024, 1:47 PM EST - Market open
Zevra Therapeutics Employees
As of December 31, 2023, Zevra Therapeutics had 69 total employees, including 65 full-time and 4 part-time employees. The number of employees increased by 33 or 91.67% compared to the previous year.
Employees
69
Change (1Y)
33
Growth (1Y)
91.67%
Revenue / Employee
$354,913
Profits / Employee
-$1,299,478
Market Cap
484.92M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Emergent BioSolutions | 1,600 |
Health Catalyst | 1,300 |
Treace Medical Concepts | 516 |
Allogene Therapeutics | 233 |
UroGen Pharma | 201 |
Monte Rosa Therapeutics | 133 |
OmniAb | 106 |
Aura Biosciences | 89 |
ZVRA News
- 8 days ago - Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting - GlobeNewsWire
- 15 days ago - Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 - GlobeNewsWire
- 21 days ago - Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - GlobeNewsWire
- 2 months ago - Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - GlobeNewsWire
- 2 months ago - Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C - GlobeNewsWire
- 2 months ago - US FDA approves Zevra's genetic disorder treatment - Reuters